Citations (23)
Keep up to date with the latest research on this topic with citation updates for this article.
Read on this site (2)
Anke van Engen, Montserrat Casamayor, Soyoung Kim, Maureen Watt & Isaac Odeyemi. (2017) “De-escalation” strategy using micafungin for the treatment of systemic Candida infections: budget impact in France and Germany. ClinicoEconomics and Outcomes Research 9, pages 763-774.
Read now
Read now
Pola de la Torre & Annette C Reboli. (2014) Micafungin: An Evidence-Based Review of its Place in Therapy. Core Evidence 9, pages 27-39.
Read now
Read now
Articles from other publishers (21)
Julia Jeck, Florian Jakobs, Melina S Kurte, Oliver A Cornely & Florian Kron. (2023) Health-economic modelling of cost savings due to the use of rezafungin based on a German cost-of-illness study of candidiasis. JAC-Antimicrobial Resistance 5:3.
Crossref
Crossref
Chin Fen Neoh, Esin Senol, Ates Kara, Ener Cagri Dinleyici, Stuart J. Turner & David C. M. Kong. (2018) Economic evaluation of micafungin versus liposomal amphotericin B (LAmB) for treating patients with candidaemia and invasive candidiasis (IC) in Turkey. European Journal of Clinical Microbiology & Infectious Diseases 37:9, pages 1777-1784.
Crossref
Crossref
C. F. Neoh, E. Senol, A. Kara, E. C. Dinleyici, S. J. Turner & D. C. M. Kong. (2017) Pharmacoeconomic evaluation of micafungin versus caspofungin as definitive therapy for candidaemia and invasive candidiasis (IC) in Turkey. European Journal of Clinical Microbiology & Infectious Diseases 37:3, pages 537-544.
Crossref
Crossref
Arnaud Pagès, Xavier Iriart, Laurent Molinier, Bernard Georges, Antoine Berry, Patrice Massip & Blandine Juillard-Condat. (2017) Cost Effectiveness of Candida Polymerase Chain Reaction Detection and Empirical Antifungal Treatment among Patients with Suspected Fungal Peritonitis in the Intensive Care Unit. Value in Health 20:10, pages 1319-1328.
Crossref
Crossref
Chin Fen Neoh, Esin Senol, Ates Kara, Ener Cagri Dinleyici, Stuart J. Turner & David C. M. Kong. (2017) Cost-effectiveness analysis of anidulafungin vs fluconazole for the treatment of invasive candidiasis (IC) in Turkey. Mycoses 60:11, pages 714-722.
Crossref
Crossref
Georg Auzinger, E. Geoffrey Playford, Christopher N. Graham, Hediyyih N. Knox, David Weinstein, Michal Kantecki, Haran Schlamm & Claudie Charbonneau. (2015) Cost-effectiveness analysis of anidulafungin for the treatment of candidaemia and other forms of invasive candidiasis. BMC Infectious Diseases 15:1.
Crossref
Crossref
Chin Fen Neoh, Monica Slavin, Sharon C.-A. Chen, Kay Stewart & David C.M. Kong. (2014) Echinocandins in the treatment of candidaemia and invasive candidiasis: clinical and economic perspectives. International Journal of Antimicrobial Agents 43:3, pages 207-214.
Crossref
Crossref
L. Drgona, A. Khachatryan, J. Stephens, C. Charbonneau, M. Kantecki, S. Haider & R. Barnes. (2013) Clinical and economic burden of invasive fungal diseases in Europe: focus on pre-emptive and empirical treatment of Aspergillus and Candida species. European Journal of Clinical Microbiology & Infectious Diseases 33:1, pages 7-21.
Crossref
Crossref
S. Grau, M. Salavert, J. Carlos Pozo Laderas, M. García Vargas, J.A. Barrueta & N. Mir. (2013) Cost-effectiveness of anidulafungin in confirmed candidaemia and other invasive Candida infections in Spain. Journal de Mycologie Médicale 23:3, pages 155-163.
Crossref
Crossref
C. F. Neoh, D. Liew, M. A Slavin, D. Marriott, S. C.-A. Chen, O. Morrissey, K. Stewart & D. C. M. Kong. (2013) Economic evaluation of micafungin versus caspofungin for the treatment of candidaemia and invasive candidiasis. Internal Medicine Journal 43:6, pages 668-677.
Crossref
Crossref
G Auzinger, G Playford, C Graham, H Narula, C Charbonneau, D Weinstein, M Kantecki, H Schlamm & M Ruhnke. (2013) Cost-effectiveness analysis of anidulafungin in the treatment of candidaemia. Critical Care 17:S2.
Crossref
Crossref
Elizabeth Dodds Ashley, Richard Drew, Melissa Johnson, Robert Danna, Dominika Dabrowski, Valery Walker, Manishi Prasad, Barbara Alexander, George Papadopoulos & John Perfect. (2012) Cost of Invasive Fungal Infections in the Era of New Diagnostics and Expanded Treatment Options. Pharmacotherapy: The Journal of Human Pharmacology and Drug Therapy 32:10, pages 890-901.
Crossref
Crossref
Elizabeth Dodds Ashley, Richard Drew, Melissa Johnson, Robert Danna, Dominika Dabrowski, Valery Walker, Manishi Prasad, Barbara Alexander, George Papadopoulos & John Perfect. (2012) Cost of Invasive Fungal Infections in the Era of New Diagnostics and Expanded Treatment Options. Pharmacotherapy: The Journal of Human Pharmacology and Drug Therapy, pages n/a-n/a.
Crossref
Crossref
M. García-Vargas, M.A. Casado, N. Mir & J.A. Barrueta. (2012) Análisis de costes de tres candinas en el tratamiento de la candidiasis invasora en pacientes adultos no neutropénicos en España. Farmacia Hospitalaria 36:4, pages 207-215.
Crossref
Crossref
Connie Parks, Girish D. Prajapati, Ritesh Kumar & Blane Schilling. (2012) Utilization Patterns of Caspofungin and Micafungin for Treatment of Invasive Fungal Infections. Infectious Diseases in Clinical Practice 20:1, pages 53-57.
Crossref
Crossref
Elizabeth Dodds Ashley. (2011) Pharmacoeconomics of antifungal therapy: current considerations. Current Opinion in Infectious Diseases 24, pages S30-S40.
Crossref
Crossref
C. F. Neoh, D. Liew, M. Slavin, D. Marriott, S. C.- A. Chen, O. Morrissey, K. Stewart & D. C. M. Kong. (2011) Cost-effectiveness analysis of anidulafungin versus fluconazole for the treatment of invasive candidiasis. Journal of Antimicrobial Chemotherapy 66:8, pages 1906-1915.
Crossref
Crossref
Shannon L. Holt & Richard H. Drew. (2011) Echinocandins: Addressing outstanding questions surrounding treatment of invasive fungal infections. American Journal of Health-System Pharmacy 68:13, pages 1207-1220.
Crossref
Crossref
Sharon C.-A. Chen, Monica A. Slavin & Tania C. Sorrell. (2011) Echinocandin Antifungal Drugs in Fungal Infections. Drugs 71:1, pages 11-41.
Crossref
Crossref
Stefan Felder, Kristin Grabe & Thomas Mayrhofer. (2013) Micafungin im Vergleich zu Caspofungin bei der Behandlung von invasiven Candida-Infektionen: Eine Kosteneffektivitätsanalyse für DeutschlandMicafungin versus caspofungin for the treatment of systemic Candida infections: A cost-effectiveness analysis for Germany. PharmacoEconomics German Research Articles 8:2, pages 71-83.
Crossref
Crossref
A.M. Bal. (2010) The echinocandins: three useful choices or three too many?. International Journal of Antimicrobial Agents 35:1, pages 13-18.
Crossref
Crossref